Johnson & Johnson’s Darzalex ambitions take a hit with scrapped I-O trials


J&J partners with Genmab announced that they will stop studies of Darzalex in combination with anti-pd-l1, since it failed to show benefit. This prompted Janssen to discontinue phase 1b/2 study and phase 1 trial examining Darzalex alongside J&J PD-1 candidate in multiple myeloma patients.

Read More of this article here.